The domestic equity markets opened lower, with Nifty 50 down 0.32% and BSE Sensex down 0.33%. Analysts suggest that despite ...

Australia on Friday blocked a A$672 million ($433 million) buyout offer for Mayne Pharma from U.S. drugmaker Cosette Pharmaceuticals, citing national interest.

Tarsus Pharmaceuticals, Inc. upgraded to Strong Buy; Xdemvy's rapid US growth and unique market lead highlight big upside.

Fintel reports that on November 20, 2025, B of A Securities maintained coverage of Agios Pharmaceuticals (NasdaqGS:AGIO) with ...

Fintel reports that on November 20, 2025, HC Wainwright & Co. maintained coverage of Agios Pharmaceuticals (NasdaqGS:AGIO) ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

4. Salesforce, Inc. (CRM) - Raymond James has established a $375 price target for Salesforce, currently trading at $237.03.

Despite STERIS' outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously ...

For the past two decades, large multinational pharmaceutical companies have increasingly withdrawn from researching medicines ...

For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably ...